Table 2.
Analysis in CKD subgroups
| Patients’ subgroup | COVID-19-related events | CKD, n | Control, n | RR (95% CI) |
|---|---|---|---|---|
| All CKD eGFR <60 ml/min/1.73 m2 (N = 67 861) | Documented Infections | 126 | 128 | 0.98 (0.76–1.30) |
| Symptomatic infections | 80 | 81 | 0.96 (0.68–1.34) | |
| Severe infections | 43 | 26 | 1.84 (0.95–2.67) | |
| Admissions | 41 | 34 | 1.34 (0.81–2.33) | |
| COVID-19-related death | 21 | 14 | 2.00 (0.99–5.20) | |
| CKD 3A eGFR 45–<60 ml/min/1.73 m2 (N = 37 428) | Documented Infections | 56 | 60 | 0.98 (0.61–1.56) |
| Symptomatic infections | 34 | 38 | 0.82 (0.47–1.39) | |
| Severe infections | 14 | 9 | 1.43 (0.57–4.31) | |
| Admissions | 16 | 12 | 0.86 (0.34–2.87) | |
| COVID-19-related death | 9 | 5 | 1.41 (0.45–7.35) | |
| CKD 3B eGFR 30–<45 ml/min/1.73 m2 (N = 22 341) | Documented Infections | 49 | 52 | 0.96 (0.63–1.42) |
| Symptomatic infections | 30 | 35 | 0.87 (0.51–1.42) | |
| Severe infections | 14 | 15 | 0.89 (0.39–1.88) | |
| Admissions | 15 | 18 | 0.83 (0.39–1.75) | |
| COVID-19-related death | 3 | 8 | 0.31 (0–1.05) | |
| CKD 4–5 eGFR 0–<30 ml/min/1.73 m2 (N = 8092) | Documented Infections | 21 | 16 | 1.19 (0.60–2.53) |
| Symptomatic infections | 16 | 8 | 1.84 (0.74–5.68) | |
| Severe infections | 15 | 2 | 6.42 (1.85–17.51) | |
| Admissions | 10 | 4 | 2.98 (0.96–12.74) | |
| COVID-19-related death | 9 | 1 | 8.81 (1.63–13.81) |
RR, risk ratio.CKD patients were divided according to stages as defined by KDIGO criteria. RRs were evaluated using the same estimator for the period 7–28 days following the second vaccine dose.